US-based biotech firm Novavax on Friday (26 November) announced that it has started working on a Covid-19 vaccine against the B.1.1.529 variant of Coronavirus that was recently detected in South Africa and has been named 'Omicron' by the World Health Organisation (WHO).
The company has said that it would have a shot prepared for testing and manufacturing purposes in the coming few weeks.
The Covid-19 shot of the company comprises of an actual version of the spike protein of the virus that cannot cause the disease but instead triggers the immune system, reports Indian Express.
Novavax is now developing a spike protein specifically based on the known genetic sequence of the newly-discovered variant.
Meanwhile, other vaccine developers like Germany's BioNTech and US-based Johnson & Johnson have said that they are testing the effectiveness of their vaccines against the ‘Omicron’ variant.
Similarly, Inovio Pharmaceuticals has also begun testing its vaccine candidate INO-4800’s effectiveness against the new variant. It will take about a couple of weeks for the testing process to complete.
The company is also designing a new vaccine candidate that will be specifically targeting the Omicron variant.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.